| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Nationwide retrospective study of hepatitis B virological response and liver stiffness improvement in 465 patients on nucleos(t)ide analogue
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Alnoor Ramji, Karen Doucette, Curtis Cooper, Gerald Yosel Minuk, Mang Ma, Alexander Wong, David Wong, Edward Tam, Brian Conway, David Truong, Philip Wong, Lisa Barrett, Hin Hin Ko, Sarah Haylock-Jacobs, Nishi Patel, Gilaad G Kaplan, Scott Fung and Carla S Coffin |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Alnoor Ramji, MD, Associate Professor, Department of Medicine, University of British Columbia, 2775 Laurel Str., Gordon and Leslie Diamond Health Care, Vancouver v6t 1z3, Canada. aramji@mail.ubc.ca |
| Key Words |
Nucleos(t)ide analog therapy; Functional cure; Hepatitis B virus surface antigen loss; Fibrosis regression; Liver stiffness measurement; Transient elastography |
| Core Tip |
In summary in this real-world diverse cohort study of chronic hepatitis B patients in Canada, long-term nucleo(s)ide analog (either 1st or 2nd generation) therapy suppresses hepatitis B virus DNA and improves hepatic inflammation and liver fibrosis, as determined by non-invasive testing (i.e., transient elastography). In patients treated for up to 5 years, none achieved hepatitis B surface antigen loss (functional cure), highlighting the need for improved therapeutic strategies to reduce the life-long burden of antiviral therapy. |
| Publish Date |
2022-08-16 11:59 |
| Citation |
Ramji A, Doucette K, Cooper C, Minuk GY, Ma M, Wong A, Wong D, Tam E, Conway B, Truong D, Wong P, Barrett L, Ko HH, Haylock-Jacobs S, Patel N, Kaplan GG, Fung S, Coffin CS. Nationwide retrospective study of hepatitis B virological response and liver stiffness improvement in 465 patients on nucleos(t)ide analogue. World J Gastroenterol 2022; 28(31): 4390-4398 |
| URL |
https://www.wjgnet.com/1007-9327/full/v28/i31/4390.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v28.i31.4390 |
